Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer

As reported in The Lancet Oncology by Pfob et al, a pooled analysis of randomized trials showed that performance of lymph node surgery for the sole purpose of determining eligibility for CDK4/6 inhibitor treatment does not appear to be a promising strategy in patients with early breast cancer. As stated by the investigators, “Omitting sentinel lymph node biopsy (SLNB) and completion axillary lymph node dissection (cALND) in early-stage breast cancer reduces morbidity without compromising overall survival or recurrence rates. However, reduced axillary surgery restricts staging information, impacting eligibility for CDK4/6 inhibitors. We evaluated the impact of omitting SLNB or cALND on CDK4/6 inhibitor eligibility and the associated benefits and harms.”

Lymph Node Surgery and CDK4/6 Inhibitor Treatment in Early Breast Cancer. As reported in The Lancet Oncology by Pfob et al, a pooled analysis of randomized trials showed that performance of lymph node surgery for the sole purpose of determining eligibility for CDK4/6 inhibitor treatment does not appear to be a promising strategy in patients with early breast cancer. As stated by the investigators, “Omitting sentinel lymph node biopsy (SLNB) and completion axillary lymph node dissection (cALND) in early-stage breast cancer reduces morbidity without compromising overall survival or recurrence rates. However, reduced axillary surgery restricts staging information, impacting eligibility for CDK4/6 inhibitors. We evaluated the impact of omitting SLNB or cALND on CDK4/6 inhibitor eligibility and the associated benefits and harms.” Study Details...